<DOC>
	<DOCNO>NCT02800655</DOCNO>
	<brief_summary>This study use ingestion sensor wearable sensor ( worn patch skin ) , new Proteus Digital Health ( PDH ) technology approve FDA , collect information patient take ARV medication . The wearable sensor record information , upload wirelessly mobile device secure computer . Together sensor mobile device transmit information study computer call digital health feedback system ( DHFS ) , give healthcare provider information patient take ARV medication . The purpose study demonstrate DHFS easy use acceptable HIV patient population ; patient persist use ; system provide valid , accurate measure adherence .</brief_summary>
	<brief_title>Digital Health Feedback System Longitudinal Measurement Medication Adherence During Initial ARV Therapy</brief_title>
	<detailed_description>This study prospective single arm open label intervention study 16 week use DHFS ARV-naive subject initiate HIV treatment . The study intervention initiation ( Phase 1 ) , persistence ( Phase 2 ) follow-up period 96 week . In phase 1 Subjects use DHFS close follow-up incorporate visit directly observe ingestion . In Phase 2 Subjects utilize DHFS natural set sporadic study visit 16 week . Eligible HIV seropositive subject least 18 year age , HIV treatment naïve , initiate antiretroviral therapy prescribe HIV practitioner receive ingestible sensor enable oral Anti-Retroviral IS-ARV either IS-R/F/TAF ( Odefsey® ) , IS-EC/F/TAF ( Genvoya® ) , IS-DTG/TDF/FTC ( Tivicay® Truvada® ) IS-DTG/TAF/FTC ( Tivicay® Descovy ® ) . The study conduct UCSD AVRC . Subjects recruit UCSD AVRC , UCSD Owen Clinic , relate affiliated UCSD HIV primary care program community HIV primary care clinic . Following 16 week intervention HIV plasma viral load continuation HIV care follow 96 week . The primary outcome accurate measure adherence i.e . number dos select IS-ARVs ingested , captured DHFS , number dos prescribe , adjust PDA . The investigator also assess acceptability feasibility longitudinal monitoring real time ingestion rate utilizing DHFS . In addition investigator evaluate ability DHFS identify subject whose longitudinal medication take timing pattern first 16 week ARV treatment put risk detectable HIV RNA level far 96 week start treatment . PHARMACOKINETIC ( PK ) SUBSTUDY A subset 15 participant prescribe IS-Dolutegravir regimen enrol PK sub-study generate project time-course drug concentration across entire study period . On Day 14 treatment sub-study participant detailed PK profile Dolutegravir obtain single dosing interval . Participants also random plasma Dolutegravir level measure 4 , 8 , 12 , 16 week DHFS monitoring.Plasma HIV-1 RNA CD4+ T-cell count measure study entry . At start IS-Tivicay , participant include PK study undergo intensive monitoring viral decay dynamic plasma HIV-1 RNA measure baseline Days 2 , 7 , 10 14 , well Weeks 4 , 8 , 12 , 16 provide dynamic range virologic suppression relative drug exposure profile generate intensive PK sample Day 14 DHFS dose history .</detailed_description>
	<criteria>1 . HIV seropositive status , document positive licensed screening confirm antibody test least two value HIV RNA ≥2,000 copies/mL AND treatment naïve , define never receive ARVs past ( exclude ARVs use preexposure prophylaxis OR postexposure prophylaxis ) . 2 . Persons ready initiate first regimen treatment HIV infection HIV provider , include either : Genvoya® Odefsey® Tivicay® : ) PLUS Truvada® Tivicay® : PLUS Descovy® 3 . Eligible antiretroviral medication possession prescription note study eligible regimen . 4 . Laboratory value obtain screen laboratory within 30 day entry : Absolute neutrophil count ( ANC ) ≥ 1,000/mm3 . Hemoglobin ≥ 9.0 g/dL . Platelet count ≥ 75,000/mm3 . AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase ≤ 3 x ULN . Total bilirubin ≤ 1.5 x ULN direct bilirubin . Serum lipase ≤ 1.5 x ULN TSH ≤ 1.5 x ULN Estimated GFR CockcroftGault equation great 50 ml/min , start treatment Tivicay® : Dolutegravir ( DTG ) PLUS Truvada® : Tenofovir disoproxil fumarate/Emtiritabine ( TDF/FTC ) Estimated GFR CockcroftGault equation great 30 ml/min , start treatment Genvoya® : Elvitegravir/Cobisistat/Tenofovir alafenamide/Emtricitabine ( E/C/F/TAF ) , Odefsey® : Riplivirine/Tenofovir alafenamide/Emtricitabine ( R/F/TAF ) , Tivicay® : Dolutegravir ( DTG ) PLUS Descovy® : Tenofovir alafenamide/Emtricitabine ( F/TAF ) HIV RNA value ( viral load ) ≤ 100,000 copies/mL , start treatment Odefsey® : Riplivirine/Tenofovir alafenamide/Emtricitabine ( R/F/TAF ) 5 . Females childbearing potential must agree use acceptable form contraception throughout protocol 6 week stop ISARV medication . 6 . Men woman age ≥ 18 year . 7 . Basic competency understand write verbal information applies DHFS use . English Spanish use study document communication . 8 . Willing follow protocol requirement . 9 . Ability use mobile device per investigator determination , wear PDH wearable sensor ( i.e. , skin condition preclude use ) . 10 . Ability willingness subject give write informed consent . 1 . Female pregnant , breastfeeding , childbearing potential disagrees use contraception throughout study period . 2 . Use prohibit medication noninformed medication ( Section 5.5.2 ) within 30 day study entry ( Day 0 ) . 3 . Known allergy/sensitivity study drug . 4 . Known sensitivity skin adhesive . 5 . Serious medical ( serious infection acute therapy medical illness ) psychiatric illness require systemic treatment and/or hospitalization subject either complete therapy clinically stable therapy , opinion investigator , least 30 day prior study entry ( Day 0 ) . 6 . Evidence major antiretroviral resistance associate mutation genotypic test baseline , prior study entry subject . Resistance test result must available review site investigator study protocol team prior enrollment ensure exclusionary resistance exists . All resistance test result scan uploaded online data collect system ( http : //cfar.ucsd.edu/intranet ) . NOTE : Subjects exclude genotype show presence HIVassociated resistance mutation list per International AIDS SocietyUSA mutation list ( update list find : http : //www.iasusa.org ) . 7 . Active drug alcohol use , dependence , condition , opinion site investigator , would significantly interfere ability follow study requirement . 8 . History pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>ARV treatment Naive</keyword>
	<keyword>Medication Adherence</keyword>
	<keyword>Digital Health Feedback System</keyword>
	<keyword>Proteus Digital Health</keyword>
</DOC>